Clinical trials: Metastatic Malignant Neoplasm to Brain
Brain Metastases
Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer
To observe the effectiveness and safety of apatinib combined with radiotherapy for brain metastasis from non-small cell lung cancer patients
- Trial name
- NCT03356600
- Testing
- Apatinib plus radiotherapy
- Volunteers
- 44 people
- Sponsor
- Shanxi Province Cancer Hospital
Breast Cancer, Lung Neoplasms
GRN1005 for Brain Metastases From Breast or Lung Cancer
Background: Brain metastases are cancer cells that have spread to the brain from primary cancers in other organs. These tumors can be removed surgically.
- Conditions
- Breast Cancer, Lung Neoplasms, Breast Neoplasms, Lung Cancer
- Trial name
- NCT01679743
- Testing
- Trastuzumab, GRN 1005
- Sponsor
- National Cancer Institute (NCI)
Brain Metastases
Improved Therapy Response Assessment in Metastatic Brain Tumors
TREATMENT is an observational study addressing the need for knowledge and adequate diagnostic biomarkers in the response assessment of patients with brain metastasis.
- Trial name
- TREATMENT (NCT03458455)
- Testing
- Magnetic Resonance Imaging, Stereotactic Radiosurgery, Ipilimumab, nivolumab or pembrolizumab
- Where
- Norway
- Volunteers
- 200 people
- Sponsor
- Oslo University Hospital
Brain Cancer, Brain Metastases
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that…
- Conditions
- Brain Cancer, Brain Metastases, Melanoma, Lung Cancer
- Trial name
- NCT04899908
- Testing
- Stereotactic Radiation, AGuIX gadolinium-based nanoparticles
- Where
- 2 sites in United States
- Volunteers
- 134 people
- Sponsor
- Brigham and Women's Hospital
Brain Metastases
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation…
- Trial name
- REVELATE (NCT04410133)
- Testing
- 18F fluciclovine
- Where
- 19 sites in United States
- Volunteers
- 151 people
- Sponsor
- Blue Earth Diagnostics
Brain Metastases, Nsclc
The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?
Patients suffering from malignancies in advanced stages often develop brain metastases, which limit both the life span and the quality of life.
- Trial name
- CyberChallenge (NCT05378633)
- Testing
- SRS, Whole Brain Radiotherapy
- Where
- Germany
- Volunteers
- 190 people
- Sponsor
- University Hospital Heidelberg
Neoplasms
Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
A phase II trial to assess the impact of afatinib (BIBW 2992) on the heart (QTcF) and the effectiveness of afatinib (BIBW 2992) in treating certain cancers.
- Trial name
- NCT00875433
- Testing
- BIBW 2992
- Where
- 4 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Brain Metastases
Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases(RAD 1002)
This study will investigate the safety, tolerability, and effectiveness of changing the order of receiving radiation therapy for treating brain cancer.
- Trial name
- RAD 1002 (NCT01252797)
- Testing
- Stereotactic Radiosurgery (15 Gy), Stereotactic Radiosurgery (12 Gy)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Cancer, Cancer
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as…
- Conditions
- Metastatic Cancer, Cancer, Solid Tumor
- Trial name
- NCT01957735
- Testing
- BP31510 monotherapy, BP31510 in combination with chemotherapy
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- BPGbio
Metastatic Malignant Neoplasm to Brain, Unspecified Adult Solid Tumor, Protocol Specific
Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
This phase I trial studies the side effects and best dose of hypofractionated radiosurgery in treating patients with large brain metastasis.
- Trial name
- NCT01705548
- Testing
- Hypofractionated Radiosurgery
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
This phase II trial studies the side effects and how well low dose ipilimumab works in combination with pembrolizumab in treating patients with melanoma that has spread to the brain.
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT03873818
- Testing
- Ipilimumab, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Malignant Neoplasm to Brain
Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis
This phase I pilot study aims to define the safety of a combined treatment of bevacizumab and whole brain radiation therapy for the treatment of patients with brain metastasis of solid tumors.
- Trial name
- NCT01332929
- Testing
- Bevacizumab
- Where
- 6 sites in France
- Volunteers
- 21 people
- Sponsor
- Centre Francois Baclesse
Primary Brain Tumor, Brain Metastases, Adult
Exploring Compensation to Maintain Cognitive Function in Adults Newly Diagnosed With Brain Cancer
Recent research indicates that variability in cognitive function for brain tumor survivors may be explained by differences in cognitive reserve (CR) and use of compensatory strategies.However, it is unknown when cognitive…
- Trial name
- NCT04075370
- Testing
- Neuropsychological Testing
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Duke University
Brain Tumor, Brain Metastases
Re-craniotomy and Complications After Elective Neurosurgery
This study is a prospective cohort study to find the incidence of re-craniotomy and predictive factors. The secondary outcomes are to find the incidence of major non-neurological complications and predictive factors.
- Conditions
- Brain Tumor, Brain Metastases, Brain Cancer, Brain Neoplasms
- Trial name
- NCT03910556
- Testing
- Propofol
- Volunteers
- 439 people
- Sponsor
- Chiang Mai University
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases
This phase II trial studies the effect of neuropsychological evaluation and intervention in maintaining quality of life after radiation therapy in patients with cancer that has spread to the brain (metastases).
- Trial name
- NCT05503251
- Testing
- Best Practice, Neuropsychological Assessment, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
This phase II trial tests how well cemiplimab works in treating patients with PD-L1 >= 50% non-small cell lung cancer (NSCLC) that has spread from where it first started (primary site) to the brain (metastases).
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT05840770
- Testing
- Biospecimen Collection, Cemiplimab, Computed Tomography
- Sponsor
- City of Hope Medical Center
NSCLC
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
EGFR mutation-positive NSCLC patients have a higher risk of developing brain metastases. The prognosis is poor for patients presenting with brain or leptomeningeal metastases at any stage, particularly those with such metastases…
- Trial name
- NCT06945705
- Testing
- furmonertinib combined with anlotinib
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Henan Cancer Hospital
HER2-positive Breast Cancer, Brain Metastases
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
This is a prospective, randomized, 2-arm, Phrase 2, superiority and multicenter study to compare the efficiency of Anti-HER2 TKI versus Pertuzumab in Combination With Dose-dense Trastuzumab and Taxane in HER2-positive breast…
- Trial name
- NCT04760431
- Testing
- Trastuzumab, Taxanes, Pertuzumab
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer
Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study
This study evaluates the safety and efficacy of Befotertinib combined with Bevacizumab as a first-line treatment for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) accompanied by brain or…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases, Leptomeningeal Metastases
- Trial name
- Better Brain (NCT06728865)
- Testing
- The treatment regimen is Befotertinib combined with Bevacizumab.
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Li-kun Chen
Malignant Melanoma
A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
This open-label, single-arm, multicenter study will evaluate the efficacy and safety in participants with metastatic melanoma who developed brain metastases.
- Trial name
- NCT01378975
- Testing
- Vemurafenib
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 146 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.